GARY M. STRAUSS, M.D.; SIGMUND A. WEITZMAN, M.D.; THOMAS T. AOKI, M.D.
Pancreatic alpha cell tumors that secrete glucagon have stimulated considerable interest recently. They have been associated with a striking and distinctive clinical syndrome characterized by the skin rash of necrolytic migratory erythema, weight loss, glucose intolerance, anemia, stomatitis, and hepatic metastases in most cases
(1). Streptozocin has been used with sporadic, though not consistent, success. Efficacy for dimethyltriazenoimidazole carboxamide (DTIC) in this disease has been suggested in a single previous case report (2). We report here a rather remarkable response to DTIC in a patient with the malignant glucagonoma syndrome.
A 43-year-old white man presented to Massachusetts General Hospital in
Learn more about subscription options.
Register Now for a free account.
STRAUSS GM, WEITZMAN SA, AOKI TT. Dimethyltriazenoimidazole Carboxamide Therapy of Malignant Glucagonoma. Ann Intern Med. 1979;90:57–58. doi: 10.7326/0003-4819-90-1-57
Download citation file:
Published: Ann Intern Med. 1979;90(1):57-58.
Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology, Pancreatic Cancer, Pancreatic Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only